About Argenxargenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.
CEO: Tim Van Hauwermeiren
CFO: Eric Castaldi
CSO: Hans de Haard
CDO: Torsten Dreier
CMO: Nicolas Leupin
Please click here for Argenx job opportunities.
Please click here for clinical trial information.
70 articles with Argenx
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
Halozyme Therapeutics, Inc. announced that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn
Argenx, based in Breda, the Netherlands, and Halozyme Therapeutics, headquartered in San Diego, CA, signed a global collaboration and license deal that lets Argenx use Halozyme’s Enhanze drug delivery technology to develop multiple products.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain
Regulated information – Inside information argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110)
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it will share the detailed data from its Phase 2 clinical trial of efgartigimod (ARGX-113) in immune thrombocytopenia (ITP)
Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).
Argenx announced today the closing of its public offering in the United States of 5,106,000 ADSs, at a price of $52.00 per ADS, for gross proceeds of approximately $266M.
12/14/2017argenx increased the Offering from the initially filed offering size of $150 million.
All of the ADSs in the proposed Offering are to be sold by argenx.
Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx.
argenx to Provide Updates on Phase I/II Clinical Trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma During American Society of Hematology Annual Meeting
The workshop will be held Monday, December 11th at 12:00 pm EST.
argenx Reports Positive Topline Results From Phase II Proof-of-Concept Trial of ARGX-113 (Efgartigimod) in Generalized Myasthenia Gravis
Favorable tolerability profile consistent with Phase 1 data.
All proposed resolutions on the agenda for this extraordinary shareholders' meeting were approved.
The event will feature guest speaker Dr. John Stanley, M.D., University of Pennsylvania School of Medicine, who will highlight the treatment landscape and unmet need in PV.
The first subject has been dosed in the Phase I clinical trial.
The company announced financial results and provided a business update for the third quarter ended September 30, 2017.